Therapeutic targeting of microenvironmental interactions in leukemia: Mechanisms and approaches
- 31 October 2009
- journal article
- review article
- Published by Elsevier BV in Drug Resistance Updates
- Vol. 12 (4-5), 103-113
- https://doi.org/10.1016/j.drup.2009.06.001
Abstract
No abstract availableKeywords
This publication has 138 references indexed in Scilit:
- Anthracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor-induced mobilization of circulating angiogenic cellsProceedings of the National Academy of Sciences of the United States of America, 2009
- Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK functionProceedings of the National Academy of Sciences of the United States of America, 2008
- Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North AmericaThe New England Journal of Medicine, 2007
- Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple MyelomaThe New England Journal of Medicine, 2007
- A Microenvironment-Induced Myeloproliferative Syndrome Caused by Retinoic Acid Receptor γ DeficiencyCell, 2007
- Rb Regulates Interactions between Hematopoietic Stem Cells and Their Bone Marrow MicroenvironmentCell, 2007
- Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxiaProceedings of the National Academy of Sciences of the United States of America, 2007
- The biology of VEGF and its receptorsNature Medicine, 2003
- Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1Nature, 1996
- Thalidomide is an inhibitor of angiogenesis.Proceedings of the National Academy of Sciences of the United States of America, 1994